Clinical value of peripheral blood circulating tumor DNA in predicting the efficacy of immunotherapy for non-small cell lung cancer

BACKGROUND: The high expression of programmed cell death 1-ligand 1 (PD-L1) is a valid biological indicator of the therapeutic benefit of pembrolizumab in non-small cell lung cancer (NSCLC) patients. However, the response rate of NSCLC patients with positive PD-L1 expression to anti-PD-1/PD-L1 thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jing, Fan, Xirong, Zhang, Jinshu, Huang, Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267936/
https://www.ncbi.nlm.nih.gov/pubmed/37324075
http://dx.doi.org/10.21037/jtd-23-379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267936/
https://www.ncbi.nlm.nih.gov/pubmed/37324075
http://dx.doi.org/10.21037/jtd-23-379

Ejemplares similares